Press Releases | Page 34 of 43

Oncotarget | Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

August 2, 2022

“In conclusion, our study provides further data on the immunologic impact of nCRT in rectal cancer.” Listen to an audio version of this press release BUFFALO, NY- August 2, 2022… read more

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

“CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.” Listen to an audio version of this press release BUFFALO, NY-… read more

Oncotarget

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

July 19, 2022

“Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.” Listen to an audio version of this press release BUFFALO, NY- July 19,… read more

Oncotarget

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of Kita-Kyushu lung… read more

Oncotarget

Oncotarget | Role of germline variants in the metastasis of breast carcinomas

July 7, 2022

“We found several gene candidates through which the host’s genetic makeup contributes to metastasis.” Listen to an audio version of this press release BUFFALO, NY- July 7, 2022 – A… read more

Oncotarget

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

July 6, 2022

“These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.” Listen to an audio version of this press release BUFFALO, NY- July 6, 2022… read more

Oncotarget

Oncotarget | New Oncology-Focused Papers Published in Volume 13

June 23, 2022

Listen to an audio version of this announcement BUFFALO, NY- June 23, 2022 – At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in… read more

PRESS RELEASE: Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

Oncotarget

Impact Journals Sponsors 2022 Ride For Roswell

June 14, 2022

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell. Listen to an audio version of this… read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in… read more

Figure 3: Similar gene expression patterns between endocrine-resistant breast cancer and triple-negative breast cancer.

Oncotarget

Novel Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression Analysis

June 8, 2022

“Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.” Listen to an audio version of this press release BUFFALO,… read more